Evaluation of the clinical value of ELISA based on MPT64 antibody aptamer for serological diagnosis of pulmonary tuberculosis

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Zhu, Changtai ^a,b   Liu, Jinming ^b   Ling, Yang ^a   Yang, Hua ^b   Liu, Zhonghua ^b   Zheng, Ruijuan ^b   Qin, Lianhua ^b   Hu, Zhongyi ^b  

^a China   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Aptamer; MPT64 antibody; SsDNA; System evolution of ligands by exponential enrichment (SELEX); Tuberculosis

Indexed keywords

APTAMER; BACTERIAL PROTEIN; DOUBLE STRANDED DNA; MPT64; PEPTIDE APTAMER; SINGLE STRANDED DNA; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; MPT64 PROTEIN, MYCOBACTERIUM TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTIBODY AFFINITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; COUGHING; DNA LIBRARY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HUMAN; LIMIT OF DETECTION; LUNG ABSCESS; LUNG CANCER; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; PNEUMONIA; PROTEIN SECONDARY STRUCTURE; PROTEIN SECRETION; REACTION TIME; SENSITIVITY AND SPECIFICITY; SEROLOGY; SPUTUM SMEAR; THORAX RADIOGRAPHY; WEIGHT REDUCTION; BLOOD; CHEMISTRY; COMBINATORIAL CHEMISTRY; EVALUATION; IMMUNOLOGY; METHODOLOGY;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; APTAMERS, NUCLEOTIDE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; SELEX APTAMER TECHNIQUE; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, PULMONARY;

EID: 84862199844     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-96     Document Type: Article

References (54)

1. World Health Organisation Global tuberculosis control:WHO Report 2011 2011, Geneva, World Health Organisation.
2. Aziz MA, Wright A. The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases. Clin Infect Dis 2005, 41(Suppl 4):S258-S262.
3. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368(9547):1575-1580. 10.1016/S0140-6736(06)69573-1, 17084757.
4. Raviglione MC, Narain JP, Kochi A. HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment. Bull World Health Organ 1992, 70(4):515-526. 2393393, 1394786.
5. Pevzner ES, Vandebriel G, Lowrance DW, Gasana M, Finlay A. Evaluation of the rapid scale-up of collaborative TB/HIV activities in TB facilities in Rwanda. BMC Public Health 2005-2009, 11:550.
6. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med 2009, 6(2):e2. 10.1371/journal.pmed.1000002, 2637921, 19209951.
7. Rasanathan K, Sivasankara Kurup A, Jaramillo E, Lonnroth K. The social determinants of health: key to global tuberculosis control. Int J Tuberc Lung Dis 2011, 15(Suppl 2):S30-S36.
8. Roche PW, Winter N, Triccas JA, Feng CG, Britton WJ. Expression of Mycobacterium tuberculosis MPT64 in recombinant Myco. smegmatis: purification, immunogenicity and application to skin tests for tuberculosis. Clin Exp Immunol 1996, 103(2)):226-232. 2200345, 8565304.
9. Harboe M, Nagai S, Patarroyo ME, Torres ML, Ramirez C, Cruz N. Properties of proteins MPB64, MPB70, and MPB80 of Mycobacterium bovis BCG. Infect Immun 1986, 52(1):293-302. 262233, 3514457.
10. Goldhofer W, Kreienberg R, Kutzner J, Lemmel EM. Influence of x-rays on the B- and T-cells in the spleen of mice and their reaction on mitogenetic substances (author's transl). Strahlentherapie 1979, 155(4):277-283.
11. Chaudhary M, Gupta S, Khare S, Lal S. Diagnosis of tuberculosis in an era of HIV pandemic: a review of current status and future prospects. Indian J Med Microbiol 2010, 28(4):281-289. 10.4103/0255-0857.71805, 20966555.
12. Christy KG, LaTart DB. Osterhoudt HW: Modifications for SDS-PAGE of proteins. Biotechniques 1989, 7(7)):692-693.
13. Carroll MW, Moss B. E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. Biotechniques 1995, 19(3):352-354. 356.
14. Kruger NJ. The Bradford method for protein quantitation. Methods Mol Biol 1994, 32:9-15.
15. Li H, Ulstrup JC, Jonassen TO, Melby K, Nagai S, Harboe M. Evidence for absence of the MPB64 gene in some substrains of Mycobacterium bovis BCG. Infect Immun 1993, 61(5):1730-1734. 280758, 8478061.
16. Roche PW, Triccas JA, Avery DT, Fifis T, Billman-Jacobe H, Britton WJ. Differential T cell responses to mycobacteria-secreted proteins distinguish vaccination with bacille Calmette-Guerin from infection with Mycobacterium tuberculosis. J Infect Dis 1994, 170(5):1326-1330. 10.1093/infdis/170.5.1326, 7963739.
17. Oettinger T, Andersen AB. Cloning and B-cell-epitope mapping of MPT64 from Mycobacterium tuberculosis H37Rv. Infect Immun 1994, 62(5):2058-2064. 186466, 7513311.
18. Abe C, Hirano K, Tomiyama T. Simple and rapid identification of the Mycobacterium tuberculosis complex by immunochromatographic assay using anti-MPB64 monoclonal antibodies. J Clin Microbiol 1999, 37(11):3693-3697. 85727, 10523576.
19. Nakamura RM, Velmonte MA, Kawajiri K, Ang CF, Frias RA, Mendoza MT, Montoya JC, Honda I, Haga S, Toida I. MPB64 mycobacterial antigen: a new skin-test reagent through patch method for rapid diagnosis of active tuberculosis. Int J Tuberc Lung Dis 1998, 2(7):541-546.
20. Nakamura RM, Einck L, Velmonte MA, Kawajiri K, Ang CF, Delasllagas CE, Nacy CA. Detection of active tuberculosis by an MPB-64 transdermal patch: a field study. Scand J Infect Dis 2001, 33(6):405-407. 10.1080/00365540152029846, 11450857.
21. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346(6287):818-822. 10.1038/346818a0, 1697402.
22. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249(4968):505-510. 10.1126/science.2200121, 2200121.
23. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, Sefah K, Yang CJ, Tan W. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A 2006, 103(32):11838-11843. 10.1073/pnas.0602615103, 1567664, 16873550.
24. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A 2003, 100(26):15416-15421. 10.1073/pnas.2136683100, 307582, 14676325.
25. Ohuchi SP, Ohtsu T, Nakamura Y. Selection of RNA aptamers against recombinant transforming growth factor-beta type III receptor displayed on cell surface. Biochimie 2006, 88(7):897-904. 10.1016/j.biochi.2006.02.004, 16540230.
26. Paul A, Avci-Adali M, Ziemer G, Wendel HP. Streptavidin-coated magnetic beads for DNA strand separation implicate a multitude of problems during cell-SELEX. Oligonucleotides 2009, 19(3):243-254. 10.1089/oli.2009.0194, 19732022.
27. Shi H, Tang Z, Kim Y, Nie H, Huang YF, He X, Deng K, Wang K, Tan W. In vivo fluorescence imaging of tumors using molecular aptamers generated by cell-SELEX. Chem Asian J 2010, 5(10):2209-2213. 10.1002/asia.201000242, 20806314.
28. Stoltenburg R, Reinemann C, Strehlitz B. FluMag-SELEX as an advantageous method for DNA aptamer selection. Anal Bioanal Chem 2005, 383(1):83-91. 10.1007/s00216-005-3388-9, 16052344.
29. Drabovich AP, Berezovski M, Okhonin V, Krylov SN. Selection of smart aptamers by methods of kinetic capillary electrophoresis. Anal Chem 2006, 78(9):3171-3178. 10.1021/ac060144h, 16643010.
30. Berezovski MV, Musheev MU, Drabovich AP, Jitkova JV, Krylov SN. Non-SELEX: selection of aptamers without intermediate amplification of candidate oligonucleotides. Nat Protoc 2006, 1(3):1359-1369. 10.1038/nprot.2006.200, 17406423.
31. Berezovski M, Musheev M, Drabovich A, Krylov SN. Non-SELEX selection of aptamers. J Am Chem Soc 2006, 128(5):1410-1411. 10.1021/ja056943j, 16448086.
32. Dwivedi HP, Smiley RD, Jaykus LA. Selection and characterization of DNA aptamers with binding selectivity to Campylobacter jejuni using whole-cell SELEX. Appl Microbiol Biotechnol 2010, 87(6):2323-2334. 10.1007/s00253-010-2728-7, 20582587.
33. Huang CJ, Lin HI, Shiesh SC, Lee GB. Integrated microfluidic system for rapid screening of CRP aptamers utilizing systematic evolution of ligands by exponential enrichment (SELEX). Biosens Bioelectron 2010, 25(7):1761-1766. 10.1016/j.bios.2009.12.029, 20061133.
34. Li S, Xu H, Ding H, Huang Y, Cao X, Yang G, Li J, Xie Z, Meng Y, Li X, et al. Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. J Pathol 2009, 218(3):327-336. 10.1002/path.2543, 19291713.
35. Tok JB, Fischer NO. Single microbead SELEX for efficient ssDNA aptamer generation against botulinum neurotoxin. Chem Commun (Camb) 2008, 16:1883-1885.
36. Tanaka Y, Akagi K, Nakamura Y, Kozu T. RNA aptamers targeting the carboxyl terminus of KRAS oncoprotein generated by an improved SELEX with isothermal RNA amplification. Oligonucleotides 2007, 17(1):12-21. 10.1089/oli.2006.0035R1, 17461759.
37. Burke DH, Gold L. RNA aptamers to the adenosine moiety of S-adenosyl methionine: structural inferences from variations on a theme and the reproducibility of SELEX. Nucleic Acids Res 1997, 25(10):2020-2024. 10.1093/nar/25.10.2020, 146680, 9115371.
38. Dastjerdi K, Tabar GH, Dehghani H, Haghparast A. Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. Biotechnol Appl Biochem 2011, 58(4):226-230. 10.1002/bab.36, 21838796.
39. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther 2006, 5(12):2957-2962. 10.1158/1535-7163.MCT-06-0172, 17172400.
40. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002, 62(14):4029-4033.
41. Guo KT, SchAfer R, Paul A, Gerber A, Ziemer G, Wendel HP. A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers. Stem Cells 2006, 24(10):2220-2231. 10.1634/stemcells.2006-0015, 16794266.
42. Kunii T, Ogura S, Mie M, Kobatake E. Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX. Analyst 2011, 136(7):1310-1312. 10.1039/c0an00962h, 21321690.
43. Zueva E, Rubio LI, Duconge F, Tavitian B. Metastasis-focused cell-based SELEX generates aptamers inhibiting cell migration and invasion. Int J Cancer 2011, 128(4):797-804. 10.1002/ijc.25401, 20473891.
44. Cerchia L, Duconge F, Pestourie C, Boulay J, Aissouni Y, Gombert K, Tavitian B, de Franciscis V, Libri D. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 2005, 3(4):e123. 10.1371/journal.pbio.0030123, 1065267, 15769183.
45. Shamah SM, Healy JM, Cload ST. Complex target SELEX. Acc Chem Res 2008, 41(1):130-138. 10.1021/ar700142z, 18193823.
46. Berezovski MV, Lechmann M, Musheev MU, Mak TW, Krylov SN. Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc 2008, 130(28):9137-9143. 10.1021/ja801951p, 18558676.
47. Cheng C, Dong J, Yao L, Chen A, Jia R, Huan L, Guo J, Shu Y, Zhang Z. Potent inhibition of human influenza H5N1 virus by oligonucleotides derived by SELEX. Biochem Biophys Res Commun 2008, 366(3):670-674. 10.1016/j.bbrc.2007.11.183, 18078808.
48. Guo KT, Ziemer G, Paul A, Wendel HP. CELL-SELEX: Novel perspectives of aptamer-based therapeutics. Int J Mol Sci 2008, 9(4):668-678. 10.3390/ijms9040668, 2635693, 19325777.
49. Dua P, Kim S, Lee DK. Patents on SELEX and therapeutic aptamers. Recent Pat DNA Gene Seq 2008, 2(3):172-186. 10.2174/187221508786241710, 19075955.
50. Chen F, Zhou J, Luo F, Mohammed AB, Zhang XL. Aptamer from whole-bacterium SELEX as new therapeutic reagent against virulent Mycobacterium tuberculosis. Biochem Biophys Res Commun 2007, 357(3):743-748. 10.1016/j.bbrc.2007.04.007, 17442275.
51. Vavvas D, D'Amico DJ. Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice. Ophthalmol Clin North Am 2006, 19(3):353-360.
52. Ulrich H, Trujillo CA, Nery AA, Alves JM, Majumder P, Resende RR, Martins AH. DNA and RNA aptamers: from tools for basic research towards therapeutic applications. Comb Chem High Throughput Screen 2006, 9(8):619-632. 10.2174/138620706778249695, 17017882.
53. Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci 2008, 63(8):879-884. 10.1093/gerona/63.8.879, 2562869, 18772478.
54. Wanchu A. Advances in serology for diagnosing TB in the HIV infected. Indian J Chest Dis Allied Sci 2005, 47(1):31-37.